NNVC ▼ -0.8% - NanoViricides, Inc. $NNVC - While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles NanoViricides declined 0.8% today despite announcing progress toward clinical trials of its antiviral candidate NV-387 for measles treatment, which could theoretically benefit from rising measles case counts globally. The modest drop suggests investors may be focused on the uncertain timeline and outcomes of clinical trials rather than the near-term revenue potential of the program. Without an approved or imminent treatment, the market appears to be taking a cautious stance on the company's development stage. 31-AUG-2026 08:30 AM ET